Melanoma Journal Articles for October 2018
Cancer Epidemiology, Biomarkers and Prevention
Reviews
An Epidemiological Review of Diet and Cutaneous Malignant Melanoma
Keming Yang, Teresa T. Fung and Hongmei Nan
DOI: 10.1158/1055-9965.EPI-18-0243 Published October 2018
BMJ
Cancer genetics
Short report
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Hildur Helgadottir, Paola Ghiorzo, Remco van Doorn, Susana Puig, Max Levin, Richard Kefford, Martin Lauss, Paola Queirolo, Lorenza Pastorino, Ellen Kapiteijn, Miriam Potrony, Cristina Carrera, Håkan Olsson, Veronica Höiom, Göran Jönsson
http://dx.doi.org/10.1136/jmedgenet-2018-105610
JAMA Dermatology
Original Investigation
October 10, 2018
Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins
Caroline C. Kim, MD1; Elizabeth G. Berry, MD2,3; Michael A. Marchetti, MD4; et alSusan M. Swetter, MD5,6; Geoffrey Lim, MD7; Douglas Grossman, MD, PhD8,9; Clara Curiel-Lewandrowski, MD10; Emily Y. Chu, MD, PhD11; Michael E. Ming, MD, MSCE11; Kathleen Zhu, BA12; Meera Brahmbhatt, MD2,13; Vijay Balakrishnan, BS2,3; Michael J. Davis, BMus2,3; Zachary Wolner, BA4; Nathaniel Fleming, BA5,6; Laura K. Ferris, MD, PhD7; John Nguyen, BA14; Oleksandr Trofymenko, BA10; Yuan Liu, PhD2; Suephy C. Chen, MD, MS2,3; for the Pigmented Lesion Subcommittee, Melanoma Prevention Working Group
JAMA Dermatol. Published online October 10, 2018. doi:10.1001/jamadermatol.2018.3359
ACTA DERMATO VENEREOLOGICA
Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response
Pablo Iglesias, Simone Ribero, Alicia Barreiro, Sebastian Podlipnik, Cristina Carrera, Josep Malvehy, Susana Puig
DOI: 10.2340/00015555-3061
ACTA DERMATO VENEREOLOGICA
Paraneoplastic Opsoclonus-Myoclonus Syndrome Preceding a Mucosal Malignant Melanoma
Flora Dresco, François Aubin, Elise Deveza, Eugeniu Revenco, Laurent Tavernier, Eve Puzenat
DOI: 10.2340/00015555-3062
Dove Press
Biomimetic quantum dot-labeled B16F10 murine melanoma cells as a tool to monitor early steps of lung metastasis by in vivo imaging
Authors Díaz-García VM, Guerrero S, Díaz-Valdivia N, Lobos-González L, Kogan M, Pérez-Donoso JM, Quest AFG
Received 15 February 2018
Accepted for publication 30 May 2018
Published 16 October 2018 Volume 2018:13 Pages 6391—6412
DOI https://doi.org/10.2147/IJN.S165565
Dove Press
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Authors Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F
Received 5 August 2018
Accepted for publication 19 September 2018
Published 17 October 2018 Volume 2018:11 Pages 7095—7107
DOI https://doi.org/10.2147/OTT.S182721
Clinical Cancer Research
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma
Allison Betof Warner and Michael A. Postow
DOI: 10.1158/1078-0432.CCR-18-1311 Published October 2018
The Lancet
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, MD ,Vanna Chiarion-Sileni, MD, Prof Rene Gonzalez, MD, Prof Jean-Jacques Grob, MD, Prof Piotr Rutkowski, MD, Charles Lance Cowey, MD, et al.
Published:October 22, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30700-9
Journal of Investigative Dermatology
Association between phenotypic characteristics and melanoma in a large prospective cohort study
Catherine M. Olsen, Nirmala Pandeya, Bridie S. Thompson, Jean Claude Dusingize, Adele C. Green, Rachel E. Neale, David C. Whiteman
for the QSkin Study
DOI: https://doi.org/10.1016/j.jid.2018.09.022
JAMA Dermatology
Observation
October 24, 2018
Herpetic Whitlow—A Case of Inadvertent Inoculation With Melanoma Viral Therapy
Jonathan M. Soh, MD1; Eva Galka, MD2; Mary Gail Mercurio, MD1
Author Affiliations
JAMA Dermatol. Published online October 24, 2018. doi:10.1001/jamadermatol.2018.3584
Dove Press
The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Authors Li P, Yang X, Feng Y, Wu L, Ma W, Ding G, Wei Y, Sun L
Received 12 February 2018
Accepted for publication 13 May 2018
Published 26 October 2018 Volume 2018:11 Pages 7521—7527
DOI https://doi.org/10.2147/OTT.S165368
Molecular Cancer Research
Signal Transduction
miR-122-5p Expression and Secretion in Melanoma Cells Is Amplified By the LPAR3 SH3–Binding Domain to Regulate Wnt1
Charnel C. Byrnes, Wei Jia, Ali A. Alshamrani, Sudeepti S. Kuppa and Mandi M. Murph
DOI: 10.1158/1541-7786.MCR-18-0460
Molecules 2018, 23(11), 2820; https://doi.org/10.3390/molecules23112820
Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells
Christin Durchschein, Antje Hufner, Beate Rinner, Alexander Stallinger, Alexander Deutsch, Birgit Lohberger, Rudolf Bauer and Nadine Kretschmer
Received: 9 October 2018 / Revised: 19 October 2018 / Accepted: 20 October 2018 / Published: 30 October 2018
International Journal of Cancer
Cancer Epidemiology
Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study
First published: 06 July 2018
https://doi.org/10.1002/ijc.31644
International Journal of Cancer
Cancer Therapy and Prevention
Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
Bin Zhao Hong Zhao Jiaxin Zhao
First published: 19 August 2018
https://doi.org/10.1002/ijc.31813
JAMA
Original Investigation
October 2018
Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation
Eszter Szalai, MD, PhD1,2; Yi Jiang, PhD3; Natasha M. van Poppelen, MD4,5; et alMartine J. Jager, MD, PhD6; Annelies de Klein, PhD5; Emine Kilic, MD, PhD4; Hans E. Grossniklaus, MD1,7
JAMA Ophthalmol. 2018;136(10):1115-1120. doi:10.1001/jamaophthalmol.2018.2986
JAMA
Original Investigation
October 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic MelanomaPooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild, MD1; James Larkin, FRCP2; Antoni Ribas, MD3; et alBrigitte Dréno, MD4; Keith T. Flaherty, MD5; Paolo A. Ascierto, MD6; Karl D. Lewis, MD7; Edward McKenna, PharmD8; Qian Zhu, PhD8; Yong Mun, PhD8; Grant A. McArthur, FRACP9,10
JAMA Oncol. 2018;4(10):1382-1388. doi:10.1001/jamaoncol.2018.2668
Journal of Clinical Oncology
ORIGINAL REPORTS
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, Ahmad A. Tarhini, Hussein A. Tawbi, Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, Nageatte Ibrahim, John M. Kirkwood, and Hassane M. Zarour
DOI: 10.1200/JCO.18.00632 Journal of Clinical Oncology – published online before print October 25, 2018